Comprehensive Pediatrics and Internal Medicine

Comprehensive Pediatrics and Internal Medicine

Comments

HEART MONTH!
The Medical Association of the State of Alabama has just announced the following:

"The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization to Pfizer for its oral antiviral drug Paxlovid to treat COVID-19. Data indicates that it is 88 percent effective in reducing the proportion of people with COVID-19-related hospitalization or death."
"Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Paxlovid should be initiated as soon as possible after diagnosis of COVID-19 and within five days of the onset of symptoms. Patients who are prescribed this treatment must have a positive SARS-CoV-2 test, be at high risk for progressing to severe COVID-19, and be age 12 years or older and weigh at least about 88 pounds. It is administered as three tablets taken together twice daily for five days. Paxlovid is not authorized for use for longer than five consecutive days."
"The medication is only available with a prescription from a healthcare provider. Customers can go to https://www.walmart.com/covidmedication and use the store locator to find the nearest store or club that is carrying this medication." You may use this information to notify your healthcare provider of the location you would like your prescription sent. Do not call the stores/pharmacies! The pharmacy staff is working diligently to dispense the COVID home testing, administer vaccines, and manage the Paxlovid orders.
"Since the COVID-19 antiviral medications are prescribed to those with COVID-19, it will only be available at Walmart and Sam's Club by curbside pickup or via drive-through pharmacy windows."

For more information on Paxlovid, visit https://www.fda.gov/media/155051/download.
SARS-CoV-2 is the virus responsible for causing the COVID-19 pandemic. We have seen this virus emerge and transform over the past two years. The US alone has over 49 million reported COVID-19 cases and over 800,000 deaths related to COVID-19. We have witnessed the development of vaccines to help protect against the SARS-CoV-2 virus. We have also seen medications emerge for the treatment of SARS-CoV-2 such as the convalescent plasma, monoclonal antibodies, remdesivir with dexamethasone, and Tocilizumab (IL-6 inhibitor). It's difficult for the public to see science in action. It can seem the medical and scientific community are not consistent in the information being provided. But you are seeing science in action, and you are receiving the information as it emerges. Now, we are seeing new mutations of the SARS-CoV-2 emerge. This is to be expected from viruses and other infectious organisms.

Vaccine Updates:

The United States of America currently have three vaccines being offered. There are two mRNA vaccines, Moderna and Pfizer/BioNTech. There is also a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector, Jansen/Johnson and Johnson. The Pfizer/BioNTech has been approved for use in ages 5 years and older. Moderna has been approved for use in ages 18 years and older. Jansen/Johnson and Johnson has been approved for use for ages 18 years and older. Moderna and Pfizer/BioNTech been approved for booster/3rd vaccines for those who meet the CDC guidelines to receive.

The CDC has reported the available vaccines are effective against prevention of severe illness and death related to SARS-CoV-2. The predominant variant circulating worldwide is the Delta variant (other variants Alpha, Beta, and Gamma). The Delta variant is highly transmissible and causes severe disease. The newer variant of interest is the Omicron variant. The Omicron variant is causing breakthrough infections in fully vaccinated individuals. Current research regarding Omicron are small studies with few study participants and the study time frames are short. At this time, it appears the Omicron variant may not be as severe as the Delta variant. Due to Omicron's high transmission and averting the vaccine as well as natual immunity, we are seeing the COVID-19 cases rise. Overtime, we will see the effects of the Omicron variant.

Though we are seeing a rise in Omicron, the Delta variant is still predominant. The available COVID-19 vaccines are effective at disease prevention, severe disease leading to hospitalization and death.

Testing Updates:

There at two types of tests to determine a current infection. The two tests are the nucleic acid amplification tests and the antigen test. Additional tests on positive samples are sent to State Labs to determine the variant of SARS-CoV-2 you may have.

There are also self-tests available for home use. If someone tests positive at home, the CDC recommends self-isolation for 10 days. If you are traveling and choose to use a self-test, please refer to the airline, airport, and destination requirements for reporting. If your illness is progressing due to the virus, please contact your primary care physician or seek urgent/emergent medical care at a nearby medical facility.

To determine past infection or immune status, you may have an antibody test performed. The test required a blood draw and sent to a reference lab for testing.

Medication Updates:

The monoclonal antibodies have emerged for treatment of SARS-CoV-2. The CDC "approved bamlanivimab plus etesevimab or casirivimab plus imdevimab as post-exposure prophylaxis (PEP) for individuals who have a history of exposure to individuals with SARS-CoV-2 infection and who are at high risk of progression to serious disease if they acquire the infection." Bamlanivimab plus etesevimab or casirivimab plus imdevimab are also approved for treatment of non-hospitalized individuals with COVID-19 infections. The data from controlled clinical trials revealed that high-risk patients who received COVID-19 monoclonal antibodies had a decrease in the risk of progression to severe disease, hospitalization, or death compared to patients who received placebo.

In hospitalized patients meeting certain criteria, Remdesivir and Dexamethasone are still recommended. For patients with rapid respiratory decline requiring intubation and possible ECMO, Tocilizumab (is an IL-6 inhibitor) is available. There are two large randomized controlled trials that reported a mortality benefit of tocilizumab in certain patients, including patients exhibiting rapid respiratory decompensation associated with an inflammatory response.

Researchers are developing an oral medication that may be able to treat the SARS-CoV-2 virus. Study trials are accepting participants. We do not currently have an oral medication to treat the SARS-CoV-2 virus.

Certain medications have not shown benefit. Hydroxychloroquine alone or with Azithromycin did not improve in-hospital mortality or the need for mechanical ventilation, or length of stay when compared to standard of care treatment.

Ivermectin has conflicting study findings. To ensure the benefit of the medication at reducing progression of SARS-CoV-2 disease, hospitalization, and death, we need randomized controlled trials with a larger cohort of study participants. The current studies do not show benefit in reducing recovery time from disease, reduction in oxygenation and progression to mechanical ventilation, or reduction in mortality.

Prevention Updates:

The CDC is continuing to recommend wearing masks while indoors, avoiding crowds, washing your hands, using hand sanitizer, physical distancing, quarantining/isolation if appropriate, and vaccines.

Should your child get vaccinated:

Currently, Pfizer/BioNTech is the only vaccine with EUA approval for ages 5 years and above.

Though the COVID-19 cases and deaths are low in children, vaccinating the 5- to 11-year-old age group further decreases COVID-19 complications such as the MIS-C syndrome and deaths related to COVID-19. MIS-C causes widespread inflammation of the heart, blood vessels, skin and other organs. The vaccines help to prevent the potential complications of COVID-19 infection in this age group. The Pfizer/BioNTech vaccine for children is a lower dose than the 12 years and above. Children have shown a significant immunologic response to the vaccine (about 90% effective) with minimal side effects at this dose. The vaccine is a two-dose series spaced out 21 days apart. Common side effects include flu-like symptoms such as fever, chills, fatigue, body aches, nausea and vomiting. Inflammation of the heart called myocarditis has not been reported in this age group. We are continuing to monitor.

In short, your child should be vaccinated. Vaccines help prevent disease and the spread of disease.

References:

Omicron Variant: What You Need to Know | CDC

CDC encourages COVID vaccination, boosters to protect against omicron variant | AAP News | American Academy of Pediatrics

Self-Testing | CDC

Interleukin-6 Inhibitors | COVID-19 Treatment Guidelines (nih.gov)

Therapies | COVID-19 Treatment Guidelines (nih.gov)
Now available! Schedule your child's COVID-19 vaccine.
https://kidsvaccine.timetap.com/
We are currently having technical difficulties with our phone system. CPIM and Dr. Jarmon would like to apologize for any inconvenience and truly appreciate your patience as we work with our IT partners through this matter. If you would like to request an appointment, please go to the "Request An Appointment" option on the website. If you are requesting information or have questions, please go to the "Contact Us" option on our website. If you have access to Epic's My Chart patient portal, please send your requests through the portal.

CPIM should receive the pediatric doses of the Pfizer vaccine the week of November 7th. We will create a link to set up an appointment for the vaccine.

Thank you for allowing Dr. Jarmon to partner in your health!
The Pfizer-BioNTech COVID-19 vaccines have now been approved for emergency use authorization for children ages 5 years to 11 years old.
Comprehensive Pediatrics and Internal Medicine, LLC will receive the pediatric dose vaccines. Once they have arrived, we will post a link for parents to schedule an appointment.
Thank you for your patience.

Sincerely,
Marquisha Jarmon, MD

We care for YOU at every stage of life! Dr. Marquisha Moore Jarmon
Board Certified Internal Medicine & Primary Care & Pediatrics

Operating as usual

02/02/2022

HEART MONTH!

12/31/2021

www.fda.gov

The Medical Association of the State of Alabama has just announced the following:

"The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization to Pfizer for its oral antiviral drug Paxlovid to treat COVID-19. Data indicates that it is 88 percent effective in reducing the proportion of people with COVID-19-related hospitalization or death."
"Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Paxlovid should be initiated as soon as possible after diagnosis of COVID-19 and within five days of the onset of symptoms. Patients who are prescribed this treatment must have a positive SARS-CoV-2 test, be at high risk for progressing to severe COVID-19, and be age 12 years or older and weigh at least about 88 pounds. It is administered as three tablets taken together twice daily for five days. Paxlovid is not authorized for use for longer than five consecutive days."
"The medication is only available with a prescription from a healthcare provider. Customers can go to https://www.walmart.com/covidmedication and use the store locator to find the nearest store or club that is carrying this medication." You may use this information to notify your healthcare provider of the location you would like your prescription sent. Do not call the stores/pharmacies! The pharmacy staff is working diligently to dispense the COVID home testing, administer vaccines, and manage the Paxlovid orders.
"Since the COVID-19 antiviral medications are prescribed to those with COVID-19, it will only be available at Walmart and Sam's Club by curbside pickup or via drive-through pharmacy windows."

For more information on Paxlovid, visit https://www.fda.gov/media/155051/download.

www.fda.gov

New Treatment Options for COVID-19: Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care 12/26/2021

New Treatment Options for COVID-19: Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care

https://www.cpimalabama.com/blog/new-treatment-options-for-covid-19

New Treatment Options for COVID-19: Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care SARS-CoV-2 is the virus responsible for the COVID-19 global pandemic. Countries are seeing a new surge of the virus due to Omicron variant (B.1.1.529 lineage).

12/06/2021

SARS-CoV-2 is the virus responsible for causing the COVID-19 pandemic. We have seen this virus emerge and transform over the past two years. The US alone has over 49 million reported COVID-19 cases and over 800,000 deaths related to COVID-19. We have witnessed the development of vaccines to help protect against the SARS-CoV-2 virus. We have also seen medications emerge for the treatment of SARS-CoV-2 such as the convalescent plasma, monoclonal antibodies, remdesivir with dexamethasone, and Tocilizumab (IL-6 inhibitor). It's difficult for the public to see science in action. It can seem the medical and scientific community are not consistent in the information being provided. But you are seeing science in action, and you are receiving the information as it emerges. Now, we are seeing new mutations of the SARS-CoV-2 emerge. This is to be expected from viruses and other infectious organisms.

Vaccine Updates:

The United States of America currently have three vaccines being offered. There are two mRNA vaccines, Moderna and Pfizer/BioNTech. There is also a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector, Jansen/Johnson and Johnson. The Pfizer/BioNTech has been approved for use in ages 5 years and older. Moderna has been approved for use in ages 18 years and older. Jansen/Johnson and Johnson has been approved for use for ages 18 years and older. Moderna and Pfizer/BioNTech been approved for booster/3rd vaccines for those who meet the CDC guidelines to receive.

The CDC has reported the available vaccines are effective against prevention of severe illness and death related to SARS-CoV-2. The predominant variant circulating worldwide is the Delta variant (other variants Alpha, Beta, and Gamma). The Delta variant is highly transmissible and causes severe disease. The newer variant of interest is the Omicron variant. The Omicron variant is causing breakthrough infections in fully vaccinated individuals. Current research regarding Omicron are small studies with few study participants and the study time frames are short. At this time, it appears the Omicron variant may not be as severe as the Delta variant. Due to Omicron's high transmission and averting the vaccine as well as natual immunity, we are seeing the COVID-19 cases rise. Overtime, we will see the effects of the Omicron variant.

Though we are seeing a rise in Omicron, the Delta variant is still predominant. The available COVID-19 vaccines are effective at disease prevention, severe disease leading to hospitalization and death.

Testing Updates:

There at two types of tests to determine a current infection. The two tests are the nucleic acid amplification tests and the antigen test. Additional tests on positive samples are sent to State Labs to determine the variant of SARS-CoV-2 you may have.

There are also self-tests available for home use. If someone tests positive at home, the CDC recommends self-isolation for 10 days. If you are traveling and choose to use a self-test, please refer to the airline, airport, and destination requirements for reporting. If your illness is progressing due to the virus, please contact your primary care physician or seek urgent/emergent medical care at a nearby medical facility.

To determine past infection or immune status, you may have an antibody test performed. The test required a blood draw and sent to a reference lab for testing.

Medication Updates:

The monoclonal antibodies have emerged for treatment of SARS-CoV-2. The CDC "approved bamlanivimab plus etesevimab or casirivimab plus imdevimab as post-exposure prophylaxis (PEP) for individuals who have a history of exposure to individuals with SARS-CoV-2 infection and who are at high risk of progression to serious disease if they acquire the infection." Bamlanivimab plus etesevimab or casirivimab plus imdevimab are also approved for treatment of non-hospitalized individuals with COVID-19 infections. The data from controlled clinical trials revealed that high-risk patients who received COVID-19 monoclonal antibodies had a decrease in the risk of progression to severe disease, hospitalization, or death compared to patients who received placebo.

In hospitalized patients meeting certain criteria, Remdesivir and Dexamethasone are still recommended. For patients with rapid respiratory decline requiring intubation and possible ECMO, Tocilizumab (is an IL-6 inhibitor) is available. There are two large randomized controlled trials that reported a mortality benefit of tocilizumab in certain patients, including patients exhibiting rapid respiratory decompensation associated with an inflammatory response.

Researchers are developing an oral medication that may be able to treat the SARS-CoV-2 virus. Study trials are accepting participants. We do not currently have an oral medication to treat the SARS-CoV-2 virus.

Certain medications have not shown benefit. Hydroxychloroquine alone or with Azithromycin did not improve in-hospital mortality or the need for mechanical ventilation, or length of stay when compared to standard of care treatment.

Ivermectin has conflicting study findings. To ensure the benefit of the medication at reducing progression of SARS-CoV-2 disease, hospitalization, and death, we need randomized controlled trials with a larger cohort of study participants. The current studies do not show benefit in reducing recovery time from disease, reduction in oxygenation and progression to mechanical ventilation, or reduction in mortality.

Prevention Updates:

The CDC is continuing to recommend wearing masks while indoors, avoiding crowds, washing your hands, using hand sanitizer, physical distancing, quarantining/isolation if appropriate, and vaccines.

Should your child get vaccinated:

Currently, Pfizer/BioNTech is the only vaccine with EUA approval for ages 5 years and above.

Though the COVID-19 cases and deaths are low in children, vaccinating the 5- to 11-year-old age group further decreases COVID-19 complications such as the MIS-C syndrome and deaths related to COVID-19. MIS-C causes widespread inflammation of the heart, blood vessels, skin and other organs. The vaccines help to prevent the potential complications of COVID-19 infection in this age group. The Pfizer/BioNTech vaccine for children is a lower dose than the 12 years and above. Children have shown a significant immunologic response to the vaccine (about 90% effective) with minimal side effects at this dose. The vaccine is a two-dose series spaced out 21 days apart. Common side effects include flu-like symptoms such as fever, chills, fatigue, body aches, nausea and vomiting. Inflammation of the heart called myocarditis has not been reported in this age group. We are continuing to monitor.

In short, your child should be vaccinated. Vaccines help prevent disease and the spread of disease.

References:

Omicron Variant: What You Need to Know | CDC

CDC encourages COVID vaccination, boosters to protect against omicron variant | AAP News | American Academy of Pediatrics

Self-Testing | CDC

Interleukin-6 Inhibitors | COVID-19 Treatment Guidelines (nih.gov)

Therapies | COVID-19 Treatment Guidelines (nih.gov)

Timeline photos 11/09/2021

Now available! Schedule your child's COVID-19 vaccine.
https://kidsvaccine.timetap.com/

11/06/2021

We are currently having technical difficulties with our phone system. CPIM and Dr. Jarmon would like to apologize for any inconvenience and truly appreciate your patience as we work with our IT partners through this matter. If you would like to request an appointment, please go to the "Request An Appointment" option on the website. If you are requesting information or have questions, please go to the "Contact Us" option on our website. If you have access to Epic's My Chart patient portal, please send your requests through the portal.

CPIM should receive the pediatric doses of the Pfizer vaccine the week of November 7th. We will create a link to set up an appointment for the vaccine.

Thank you for allowing Dr. Jarmon to partner in your health!

11/03/2021

The Pfizer-BioNTech COVID-19 vaccines have now been approved for emergency use authorization for children ages 5 years to 11 years old.
Comprehensive Pediatrics and Internal Medicine, LLC will receive the pediatric dose vaccines. Once they have arrived, we will post a link for parents to schedule an appointment.
Thank you for your patience.

Sincerely,
Marquisha Jarmon, MD

Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care Hoover, AL: Comprehensive Pediatrics and Internal Medicine 10/30/2021

Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care Hoover, AL: Comprehensive Pediatrics and Internal Medicine

The FDA has authorized the use of the Pfizer/BioNTech COVID-19 vaccine for children ages 5 years to 11 years old. The CDC Advisory Committee on Immunization Practices (ACIP) will meet on November 2nd and 3rd to further evaluate the data and safety of the vaccine for this age group. The vaccines will become available after final approval from ACIP and the CDC director.

If you are interested in vaccinating your child against COVID-19, contact Dr. Marquisha D. Moore Jarmon through our website www.cpimalabama.com.

Marquisha D Moore Jarmon, MD: Board Certified Internal Medicine & Primary Care Hoover, AL: Comprehensive Pediatrics and Internal Medicine Trusted Board Certified Internal Medicine & Primary Care serving Hoover, AL. Contact us at 205-225-7188 or visit us at 430 Emery Drive, Suite 200, Hoover, AL 35244: Comprehensive Pediatrics and Internal Medicine

10/01/2021

Pfizer COVID-19 Booster/3rd doses are now available.

The U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in:
Individuals 65 years of age and older;
Individuals 18 through 64 years of age at high risk of severe COVID-19; and
Individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19. This includes Frontline workers: health care workers, teachers, police and prison staff, daycare workers, grocery store workers, and others. Contact your physician to see if you qualify.
Currently, the FDA has not approved EUA for COVID-19 vaccine dosing for children under the age of 12. Once the Pfizer/BioNTech vaccine is available and FDA approved, children age 5y to 11y will be able to receive a reduced dose (10ug) in two doses 21 days apart. Approval may come in November 2021.

CPIM offers COVID-19 testing, COVID-19 vaccination (Pfizer), and Monoclonal Antibody Treatment (Regen-CoV subcutaneous injection). Please call to schedule your appointment.

08/18/2021

The Advisory Committee on Immunization Practices (ACIP) recommends a 3rd dose of mRNA COVID-19 vaccine for high risk patients. You are high risk if you have the following conditions:
Receiving active cancer treatment for tumors or cancers of the blood
Received an organ transplant and are taking medicine to suppress the immune system
Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
Advanced or untreated HIV infection
Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

Vaccines are still available for 1st and 2nd doses.

You do not need insurance to receive the COVID-19 vaccine. There is a federal program that covers the vaccine and administration of the vaccine for you.

You do not need to pay a deductible of copay to receive the COVID-19 vaccine. There is a federal program that will cover what is not covered by the insurance.

This vaccine is "FREE"! Vaccines prevent and protect!

When you are ready to receive the COVID-19 vaccine, we will have it available for you. We are offering the Pfizer/Bio-NTech vaccine. Visit www.cpimalabama.com to email Dr. Jarmon with questions or request an appointment.

The ACIP has not made recommendations regarding booster shots for those who received the Johnson and Johnson's Janssen vaccine.

07/25/2021

Please share with your friends and loved ones.
Vaccination is the key to prevention!

07/24/2021

CPIM had a wonderful week with Childcare Resources Head Start Registration and Screening Week. CCR is accepting applications for the Early Head Start program and Head Start Program. Go to https://www.ccr-bhm.org/ for more information.

Also, tickets are available for the Annual Fairytale Ball! Let's help support CCR.

Alabama promoting COVID-19 vaccination in TikTok contest 07/18/2021

Alabama promoting COVID-19 vaccination in TikTok contest

Let's get our COVID-19 vaccines!

Alabama promoting COVID-19 vaccination in TikTok contest Alabama is turning to social media to encourage more people to get vaccinated against COVID-19.

Timeline Photos 05/13/2021

COVID vaccines are now available for children ages 12 years to 15 years old

https://medspluscovidvaccineclinics.timetap.com/#/

Shelby County Alabama 04/07/2021

Shelby County Alabama

Shelby Baptist COVID-19 vaccine clinic in Columbiana:
We have over 350 1st shot clinic openings at our Columbiana Clinic (Old Mill Square) for this Friday, April 9th.

https://shelbyvax.as.me/schedule.php

Shelby County Alabama Schedule your appointment online Shelby County Alabama

04/05/2021

Comprehensive Pediatrics and Internal Medicine would like to introduce you to Live Love and Line Dance with Katesha Reynolds Cole. Zoom classes are offered Tuesdays and Wednesdays from 6pm to 7pm. Zoom ID 8803296658. Check out our website for Katesha's bio.

Our journey to a healthier you begins now!

Check out Comprehensive Pediatrics and Internal Medicine: Marquisha Moore Jarmon, MD. 04/03/2021

Check out Comprehensive Pediatrics and Internal Medicine: Marquisha Moore Jarmon, MD.

It's time to vote for The Best Pediatric Practice in Hoover! You may vote daily until April 16th.

Click the following link to vote:
https://shelbycountyreporter.secondstreetapp.com/og/d3117924-bc8b-4ceb-a9c8-f56e4adc7b1e/gallery/274218333

Check out Comprehensive Pediatrics and Internal Medicine: Marquisha Moore Jarmon, MD. Hoover's Magazine - Hoover's Best 2021

03/31/2021

MedsPLUS/CPIM COVID Vaccine Clinics

COVID Vaccine Clinic Saturday, April 3, 2021!
Appointment Required.
Registration Link: https://medsplustrueloveclinic.timetap.com

MedsPLUS/CPIM COVID Vaccine Clinics Schedule an appointment online, book online

Telephone

Address

430 Emery Drive, Suite 200
Hoover, AL
35244

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm
Saturday 9am - 12:30pm

Other Medical & Health in Hoover (show all)
ADHD Clinic of Hoover ADHD Clinic of Hoover
1 Chase Corporate Drive
Hoover, 35244

Diagnosing and treating ADHD with latest evidence based methods emphasizing modifying behavior to adapt, improvise and overcome to graduate off medication eventually. We pursue together to overcome the boredom of desk and cubicle for greater challenge!

Alabama Kidney Foundation Alabama Kidney Foundation
265 Riverchase Parkway East Suite 106
Hoover, 35244

The Alabama Kidney Foundation serves Kidney patients by providing financial assistance, education, and support services. The Foundation provides public education to promote organ donation awareness and prevention of kidney disease.

Legacy Personal Fitness Legacy Personal Fitness
4555 Southlake Pkwy
Hoover, 35244

Strength Training.Aerobic Conditioning.Weight Management

American Red Cross of Alabama American Red Cross of Alabama
700 Caldwell Trace
Hoover, 35244

This chapter page is used to post relevant local content highlighting our mission and connecting us with the communities of Alabama.

Thompson Training Thompson Training
Data Dr
Hoover, 35244

At Thompson Training We cover sports specific training as well as personal training. We provide meal plans, body fat analysis as well as motivation to live a healthier lifestyle and love what you see in the mirror.

OHD OHD
2687 John Hawkins Pkwy
Hoover, 35244

Welcome to the Official page for OHD. The manufacturers of the OHD QuantiFit2 mask fit tester and North American Distributor for Svantek.

Camellia Women's Imaging Camellia Women's Imaging
2068 Valleydale Road
Hoover, 35244

We provide the women of Alabama compassionate breast imaging services with same day results, DEXA, tomosynthisis, 3D mammogram, ultrasound, and biopsies.

SarahC & Associates, LLC SarahC & Associates, LLC
1678 Montgomery Hwy, Ste 104, # 339
Hoover, 35216

SarahC & Associates, LLC provides Certified Legal Nurse Consultant services to law firms representing clients in medical related cases.